drugset / Trial / NCT00555841

Safety and Efficacy of ALC in Breast Cancer in Subjects With Fatigue

NCT00555841

Phase 2 Terminated 27 enrolled Sigma-Tau Research, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to evaluate the efficacy and safety of ALC in the treatment of non-anemic, breast cancer subjects who develop moderate or severe fatigue during adjuvant radiotherapy.

Timeline

Start
2007-03
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Acetylcarnitine Small molecule 1 g Oral

Indications